Nintedanib attenuates peritoneal fibrosis by inhibiting mesothelial‐to‐mesenchymal transition, inflammation and angiogenesis

Nintedanib, an Food and Drug Administration (FDA) approved multiple tyrosine kinase inhibitor, exhibits an anti‐fibrotic effect in lung and kidneys. Its effect on peritoneal fibrosis remains unexplored. In this study, we found that nintedanib administration lessened chlorhexidine gluconate (CG)‐indu...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Feng, Yu, Chao, Qin, Huan, Zhang, Shenglei, Fang, Lu, Wang, Yi, Wang, Jun, Cui, Binbin, Hu, Susie, Liu, Na, Zhuang, Shougang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8256343/
https://www.ncbi.nlm.nih.gov/pubmed/33949772
http://dx.doi.org/10.1111/jcmm.16518

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8256343/
https://www.ncbi.nlm.nih.gov/pubmed/33949772
http://dx.doi.org/10.1111/jcmm.16518

Ejemplares similares